BPMC - Blueprint Medicines Corp

129.46
0.180   0.139%

Share volume: 2,980,995
Last Updated: 07-17-2025
Pharmaceutical Products/Pharmaceutical Preparations: 3.31%

PREVIOUS CLOSE
CHG
CHG%
$129.28
0.18
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 11%
Dept financing 6%
Liquidity 75%
Performance 60%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0.08%
3 Months
32.77%
6 Months
37.81%
1 Year
38.67%
2 Year
152.56%
Key data
Stock price
$129.46
P/E Ratio 
0.00
DAY RANGE
$129.30 - $129.55
EPS 
-$2.51
52 WEEK RANGE
$73.04 - $129.65
52 WEEK CHANGE
$35.53
MARKET CAP 
5.656 B
YIELD 
N/A
SHARES OUTSTANDING 
64.582 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-31-2025
BETA 
1.76
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
$11,294,301
Company detail
CEO: Kathryn Haviland
Region: US
Website: blueprintmedicines.com
Employees: 640
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Blueprint Medicines Corporation develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor, is developing Fisogatinib.

Recent news